deltatrials
Terminated PHASE1 INTERVENTIONAL 1-arm NCT02817113

Study of NC-6004 in Combination With 5-FU and Cetuximab in Patients With Head and Neck Cancer

Phase I Study of NC-6004 in Combination With 5-FU and Cetuximab as First-line Treatment in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

Sponsor: NanoCarrier Co., Ltd.

Conditions Head and Neck Neoplasms
Interventions 5-FU Cetuximab NC-6004
Updated 10 times since 2017 Last updated: Apr 29, 2021 Started: Jun 30, 2016 Primary completion: Sep 30, 2018 Completion: Sep 30, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Strategy change

Other Head and Neck Neoplasms trials with similar outcome

Browse all Head and Neck Neoplasms trials

Listed as NCT02817113, this PHASE1 trial focuses on Head and Neck Neoplasms and remains terminated or withdrawn. Sponsored by NanoCarrier Co., Ltd., it has been updated 10 times since 2016, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotRecruiting~Feb 2017 – ~Jun 2018 · 16 months · monthly snapshotRecruiting~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshotRecruiting~Jul 2018 – ~Oct 2020 · 27 months · monthly snapshotUnknown Status~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshotTerminated~Jan 2021 – ~May 2021 · 4 months · monthly snapshotTerminated~May 2021 – ~Jul 2024 · 38 months · monthly snapshotTerminated~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotTerminated~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshotTerminated~Sep 2025 – present · 10 months · monthly snapshotTerminated

Change History

10 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1

  4. May 2021 — Jul 2024 [monthly]

    Terminated PHASE1

  5. Jan 2021 — May 2021 [monthly]

    Terminated PHASE1

▶ Show 5 earlier versions

  1. Oct 2020 — Jan 2021 [monthly]

    Terminated PHASE1

    Status: Unknown Status → Terminated

  2. Jul 2018 — Oct 2020 [monthly]

    Unknown Status PHASE1

    Status: Recruiting → Unknown Status

  3. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE1

  4. Feb 2017 — Jun 2018 [monthly]

    Recruiting PHASE1

  5. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE1

    First recorded

Jun 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • NanoCarrier Co., Ltd.
  • Orient Europharma Co., Ltd.
Data source: Orient Europharma Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations